Imatinib, a selective inhibitor of BCR-Abl and c-kit receptor tyrosine kinase, is a clear example of the success of targeted therapy for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.